<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72045">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01720342</url>
  </required_header>
  <id_info>
    <org_study_id>EASE Enable</org_study_id>
    <nct_id>NCT01720342</nct_id>
  </id_info>
  <brief_title>Enable® Aortic Sutureless Bioprosthesis Evaluation</brief_title>
  <acronym>EASE</acronym>
  <official_title>Enable® Aortic Sutureless Bioprosthesis Evaluation: A Post-market Release Non-interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <authority>Switzerland: Ethikkommission</authority>
    <authority>France: Conseil National de l'Ordre des Médecins</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EASE Enable study is intended to collect additional data on the clinical outcomes of the
      Medtronic Enable® Aortic Bioprosthesis in &quot;real world&quot; patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EASE Enable study is intended to characterize the clinical performance of the Medtronic
      Enable® aortic bioprosthesis in a post-market real-world setting.

      This is a Non-randomized, prospective, non-interventional multi-center post-market release
      (PMR) study. Up to 800 subjects will be enrolled at up to 40 centers in Europe. After aortic
      valve replacement with the Enable® aortic bioprosthesis, each patient will have routine
      follow-up visits at the following intervals: at 30 days post-implant (at 30 days
      post-implant or prior to hospital discharge, whatever comes first), within 6 months
      following implantation, 1 year and annually thereafter up to 5 years post-implant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change from Baseline in Clinical performance during implant procedure, at 30 days post-implant (or prior to hospital discharge, whatever comes first), within 6 months post-operation, 1 year and annually thereafter up to 5 years post-procedure.</measure>
    <time_frame>During implant procedure, at 30 days post-implant (or prior to hospital discharge, whatever comes first), within 6 months post-operation, 1 year and annually thereafter up to 5 years post-procedure.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The early and late (up to five years) clinical performance of the Enable® aortic bioprosthesis will be characterized. Measures of clinical performance will include hemodynamic performance by echocardiography, New York Heart Association (NYHA) Functional Classification and safety (SAEs, ADEs, SADEs).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Aortic Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>aortic valve stenosis, aortic valve insufficiency</arm_group_label>
    <description>Patients with aortic valve stenosis, aortic valve insufficiency or a combination of the two who require aortic valve replacement and who are selected to be treated with the Enable® aortic bioprosthesis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Aortic Valve Replacement surgery</intervention_name>
    <description>Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.</description>
    <arm_group_label>aortic valve stenosis, aortic valve insufficiency</arm_group_label>
    <other_name>Medtronic ATS 3f Enable® Aortic Bioprosthesis (Model 6000)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with aortic valve stenosis, aortic valve insufficiency or a combination of the
        two who require aortic valve replacement are eligible for this study, if they meet all
        study inclusion criteria and none of the exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with aortic valve stenosis, aortic valve insufficiency or a combination of
             the two.

          -  Patient requires replacement of his/her native aortic valve with a bioprosthesis with
             or without concomitant procedures.

          -  Patient is above the minimum age as required by local regulations to be participating
             in a clinical study.

          -  Patient is willing to return to the implant site for follow-up visits.

          -  Patient has been adequately informed of this clinical study and is willing to sign
             the patient Data Release Form.

        Exclusion Criteria:

          -  Patient requires replacement of two or more valves.

          -  Patient who underwent previous aortic valve replacement (AVR).

          -  Patient with native bicuspid aortic valve.

          -  Patient with active endocarditis or other systemic infection.

          -  Patient dilatation of the ascending aorta, deformations or irregular aortic annulus
             or ascending aorta geometry as seen via preoperative imaging.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Otto Dapunt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Oldenburg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Vanoni</last_name>
    <phone>+31 (0)43 3566566</phone>
    <email>christian.vanoni@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf (UKD)</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Payam Akhyari</last_name>
      <phone>+49 (0) 211 - 8 11 79 25</phone>
      <email>payam.akhyari@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Artur Lichtenberg, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover (MHH)</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefanie Zimmermann</last_name>
      <phone>0511 532-5061</phone>
      <email>Zimmermann.Stefanie@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Malakh Lal Shrestha, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster (UKM)</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg GmbH</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pia Modersitzki-Osan</last_name>
      <phone>0049 441 403 2820</phone>
      <email>Modersitzki-Osan.Pia@klinikum-oldenburg.de</email>
    </contact>
    <investigator>
      <last_name>Otto Dapunt, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Acri</last_name>
      <phone>0731-500 54303</phone>
      <email>Patrizia.Acri@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Liebold, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Luigi Sacco</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Carrettoni</last_name>
      <phone>02 3904.2333</phone>
      <email>carrettoni.silvia@hsacco.it</email>
    </contact>
    <investigator>
      <last_name>Carlo Antona, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Germ van der Tempel</last_name>
      <phone>+31 55 2863732</phone>
      <email>j.van.der.tempel@ZNB.nl</email>
    </contact>
    <investigator>
      <last_name>Hafid Amrane, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eline Bruggemans, MSc</last_name>
      <phone>+31 71 526 4581</phone>
      <email>e.f.bruggemans@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>Robert Klautz, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lourdes Viedma</last_name>
      <email>lviedma.hgugm@salud.madrid</email>
    </contact>
    <investigator>
      <last_name>Angel G. Pinto, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospiten Rambla</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduard Permanyer, Dr.</last_name>
      <phone>+34 620 75 77 21</phone>
      <email>eduard.permanyer@hospiten.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Llorens, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Englberger, PD Dr. med.</last_name>
      <phone>+41 (0)31 632 15 71</phone>
      <email>lars.englberger@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Dorothee Keller</last_name>
      <phone>+41 31 632 3606</phone>
      <email>Dorothee.Keller@insel.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Lars Englberger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Martens S, Sadowski J, Eckstein FS, Bartus K, Kapelak B, Sievers HH, Schlensak C, Carrel T. Clinical experience with the ATS 3f Enable® Sutureless Bioprosthesis. Eur J Cardiothorac Surg. 2011 Sep;40(3):749-55. doi: 10.1016/j.ejcts.2010.12.068. Epub 2011 Feb 20.</citation>
    <PMID>21342776</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 23, 2013</lastchanged_date>
  <firstreceived_date>October 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medtronic Enable® aortic bioprosthesis</keyword>
  <keyword>Aortic valve stenosis</keyword>
  <keyword>Aortic valve insufficiency</keyword>
  <keyword>&quot;Real world&quot; patients</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
